IRIS
ORSI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.457
EU - Europa 1.411
AS - Asia 990
SA - Sud America 177
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 18
OC - Oceania 8
Totale 4.173
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.352
RU - Federazione Russa 670
IT - Italia 435
SG - Singapore 307
CN - Cina 306
BR - Brasile 144
HK - Hong Kong 107
VN - Vietnam 88
BD - Bangladesh 69
CA - Canada 60
DE - Germania 55
GB - Regno Unito 45
FR - Francia 44
SE - Svezia 43
IN - India 33
NL - Olanda 27
PL - Polonia 18
FI - Finlandia 17
MX - Messico 17
AR - Argentina 16
ES - Italia 14
JP - Giappone 10
ZA - Sudafrica 10
AT - Austria 8
AU - Australia 8
ID - Indonesia 8
TR - Turchia 8
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
KR - Corea 6
CO - Colombia 5
EC - Ecuador 5
HN - Honduras 5
IE - Irlanda 5
IQ - Iraq 5
MY - Malesia 5
PK - Pakistan 5
BH - Bahrain 4
JO - Giordania 4
PT - Portogallo 4
VE - Venezuela 4
AL - Albania 3
BE - Belgio 3
CW - ???statistics.table.value.countryCode.CW??? 3
CZ - Repubblica Ceca 3
IL - Israele 3
JM - Giamaica 3
LT - Lituania 3
PR - Porto Rico 3
RO - Romania 3
DK - Danimarca 2
EE - Estonia 2
GT - Guatemala 2
HR - Croazia 2
IR - Iran 2
NP - Nepal 2
PY - Paraguay 2
SA - Arabia Saudita 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UA - Ucraina 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CL - Cile 1
EG - Egitto 1
EU - Europa 1
GH - Ghana 1
GP - Guadalupe 1
GR - Grecia 1
KE - Kenya 1
LK - Sri Lanka 1
MD - Moldavia 1
MV - Maldive 1
NG - Nigeria 1
NI - Nicaragua 1
QA - Qatar 1
TN - Tunisia 1
UZ - Uzbekistan 1
VC - Saint Vincent e Grenadine 1
ZW - Zimbabwe 1
Totale 4.065
Salva come PNG Salva come JPEG
Città #
Singapore 195
Ashburn 177
San Jose 159
Moscow 149
Dallas 132
Hong Kong 104
Milan 92
Beijing 56
New York 49
Shanghai 46
Council Bluffs 45
Phoenix 42
Los Angeles 38
Santa Clara 38
Boardman 36
Rome 36
Hefei 31
Lauterbourg 30
Naples 30
Ho Chi Minh City 27
Hanoi 22
Warsaw 18
Brooklyn 16
Cesano Boscone 14
Chicago 13
Montreal 13
Orem 13
Amsterdam 12
Bologna 11
Brescia 11
Buffalo 11
London 11
Atlanta 10
Boston 10
Chennai 10
Nuremberg 10
Stockholm 10
São Paulo 10
Helsinki 9
Munich 9
Seattle 9
Campinas 8
Frankfurt am Main 8
Mexico City 8
New Orleans 8
North Bergen 8
Palermo 8
Rio de Janeiro 8
Tokyo 8
Toronto 8
Denver 7
Lawrence 7
Miano 7
Mumbai 7
Princeton 7
Washington 7
Caxias do Sul 6
Falkenstein 6
Hyderabad 6
Johannesburg 6
Manchester 6
Perugia 6
Richmond 6
Sydney 6
Turin 6
Carlsbad 5
Haiphong 5
Houston 5
Lappeenranta 5
Miami 5
Ottawa 5
Padua 5
Pisa 5
San José 5
The Dalles 5
Vienna 5
Berlin 4
Brasília 4
Catania 4
Charlotte 4
Dhaka 4
Dublin 4
Florence 4
Guangzhou 4
Las Vegas 4
Manama 4
New Haven 4
San Francisco 4
Amman 3
Baton Rouge 3
Bellpuig 3
Bogotá 3
Brussels 3
Chesapeake 3
Cincinnati 3
Da Nang 3
Dubai 3
Essen 3
Fermo 3
Figino 3
Totale 2.071
Salva come PNG Salva come JPEG
Nome #
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study 212
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 178
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 177
ANALYSIS OF THE ACTIVITY OF NOVEL RADIOSENSITIZERS AND SYSTEMIC TREATMENTS IN PANCREATIC ADENOCARCINOMA: A ROAD MAP TO IMPROVE THE OUTCOME IN LOCALLY ADVANCED DISEASE. 175
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 150
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 146
DIAGNOSTIC DELAY AT DIAGNOSIS AND TIME-TO-TREATMENT INFLUENCE OVERALL SURVIVAL OF PANCREATIC CANCER PATIENTS 142
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants 137
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy 134
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma 127
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 114
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 113
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 112
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence 110
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 107
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 103
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 103
Lessons and open questions in borderline resectable pancreatic cancer 101
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease 99
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 99
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 98
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 97
The impact of nutritional status on pancreatic cancer therapy 97
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey. 97
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma 96
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 94
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples 92
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 87
Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? 83
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 77
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 76
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants 71
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 70
Pancreatic cancer: still a cold case? 62
The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis 59
Long-term Outcomes of EUS-guided Gastroenterostomy (LONG-RANGE study): a prospective cohort study tracking symptom recurrence, reintervention timelines and stent modifications over time. 58
Long-term Outcomes of endoscopic ultrasound-guided Gastroenterostomy (LONG-RANGE study): a prospective cohort study tracking symptom recurrence, reintervention timelines and stent modifications over time 53
Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. 46
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 34
Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 26
Clinical implications and biomarkers in the PACT-21 CASSANDRA trial – Authors' reply 24
Management of Patients with Suspected Hypersensitivity to Chemotherapy Drugs: A Practical Approach in a Tertiary Care Setting 19
Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma 18
Totale 4.173
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 0 5 3 0 0 1
2022/202368 14 11 5 0 1 16 3 10 2 0 6 0
2023/2024157 12 9 12 31 15 18 5 15 4 10 5 21
2024/2025575 39 11 19 22 29 59 85 76 56 65 54 60
2025/20262.414 190 160 130 254 215 79 190 187 639 141 110 119
2026/2027950 229 221 151 349 0 0 0 0 0 0 0 0
Totale 4.173